Fibronectin Identified as Key Driver of APOE4-Linked Brain Barrier Breakdown in Alzheimer's

Blood-brain barrier dysfunction is increasingly recognized as an early and potentially causal feature of Alzheimer's disease, not merely a downstream consequence. It is especially severe in carriers of the APOE ε4 allele — the strongest known genetic risk factor for late-onset Alzheimer's — yet the molecular chain linking APOE4 to vascular failure has remained poorly defined. This study, published in Nature Aging, provides a mechanistic answer.

Using postmortem human brain tissue from Alzheimer's patients, human three-dimensional vascular organoid models, and in vivo animal experiments, the research team showed that astrocyte-derived fibronectin (encoded by the FN1 gene) is overproduced and excessively deposited around brain blood vessels under the combined influence of APOE4, amyloid-beta42, and neuroinflammatory signals. Fibronectin is a large extracellular matrix glycoprotein normally important for tissue structure, but in excess it becomes pathological.

Mechanistically, perivascular fibronectin accumulation was sufficient on its own to cause BBB leakage. The protein disrupts VEGF, HB-EGF, and IGF-1 signaling — growth factors essential for maintaining endothelial integrity — by activating integrin receptors that trigger focal adhesion kinase signaling, effectively blocking the trophic support that keeps brain vessels sealed.

Critically, the team demonstrated rescue: genetically or pharmacologically reducing fibronectin, or independently restoring growth factor signaling, repaired BBB integrity in both cell culture and animal models. Clinical datasets corroborated the experimental findings, linking FN1 expression to vascular pathology in human Alzheimer's brains.

The implications are significant. FN1 represents a druggable gliovascular target sitting downstream of APOE4 and amyloid, potentially explaining why APOE4 carriers have worse cerebrovascular outcomes. Three authors hold patents on FN1-targeted therapeutic approaches and have co-founded KVM Therapeutics, signaling active translation efforts. A key caveat is that this summary is based on the abstract only; full mechanistic details and dataset sizes are not yet assessable.